Back to Authors

Rubinger, Morel

A5002628051 | I4210088414

Mayo Clinic

CancerCare Manitoba

Citations 1

A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial

Blood | January 8, 2013 | Volume: 121 | Issue: 9 | Pages: 1517-1523

10.1182/blood-2012-09-451872 | PMID 23297129

Key Points Thalidomide and prednisone maintenance after transplantation improves progression-free but not overall survival.